Press communication
Lund, Sweden, January 8 2024
This is a translation of the Swedish press release published 2024-01-08
Neola Medical AB (publ) will be present at the investor conference J.P. Morgan Healthcare Conference in San Francisco in January 2024. CEO Hanna Sjöström will be on-site for meetings with investors and industry partners ahead of the market launch of Neola® in the USA.
The annual J.P. Morgan Healthcare Conference is held from January 8 to 11, 2024. The conference is the largest international platform connecting companies and investors in the Life Science industry. The event is attended by both major global corporations, innovative emerging companies, and investors with a focus on Life Science. In connection with the conference, CEO Hanna Sjöström will also have meetings with investors and potential industry partners.
“I look forward to being back at the J.P. Morgan Healthcare Conference in San Francisco. It is a valuable opportunity to showcase the company on an international stage, which is crucial as we are now approaching a market launch. We have several international investors and industry partners who have followed the company for a long time, and I am excited to present the significant progress that has taken place in the business during 2023,” says Hanna Sjöström, CEO of Neola Medical.
More information about the J.P. Morgan Healthcare Conference:
The J.P. Morgan Healthcare Conference is organized for the 42nd time. It is the largest investor conference in the industry, bringing together global industrial leaders, rapidly growing development companies, innovative technological creators, and investors. For more information:
https://www.jpmorgan.com/solutions/cib/insights/health-care-conference.
For further information, contact:
Hanna Sjöström, CEO Neola Medical, phone: +46 (0)760-10 71 16, e-mail: hanna.sjostrom@neolamedical.com
Neola Medical AB (publ) develops medical technology device for continuous monitoring of preterm born infants’ lungs. Immediate detection of complications provides the possibility of early treatment and improved health care. The patented technology is based on a spectroscopic method developed at Lund University in Sweden. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB.